Our People Our Story
Intelligence is the ability to adapt to change - Stephen Hawking
Stemnovate's pioneerig platform for targeted drug development is truly unique. We account for individual variations in patients' genetics, physiology, and health. It enables the most precise, carefully targeted drug development from the earliest stages of the process.
As a result, we deliver a safer, more cost-effective, and best drug discovery for humans. Preventing the needless loss of countless animal lives in a process that up until now has failed to predict accurate human responses.
Stemnovate has the best human and multispecies animal platforms to advance medical research and drug discovery.
Dr Ruchi Sharma
CEO & CSO
Dr Ruchi, is cofounder of Stemnovate Limited, she is driven by her passion for taking the benefits of research and applying them to products and technology to make a significant and positive difference in the real world. She is the ‘# One to watch’ entrepreneur of 2020 in the UK and is leading prestigious grants and international industrial partnerships. Dr Sharma obtained a PhD from the world-renowned Roslin Institute at the University of Edinburgh, followed by a post-doctorate in the exciting field of cellular reprogramming at the University of Cambridge. She is also a veterinarian and supports inventions for better animal health while reducing animal testing. With a firm focus on partnerships and collaboration, Dr Sharma believes that we can create a better world through innovation.
Our Partners
Babraham Institute, Cambridge, Alzheimer’s research
Stemnovate Ltd. and Dr Nick Ktistakis from the Babraham Institute will support a proof-of-principle project to understand how the cellular quality control process of autophagy targets protein aggregates in the brain. Using blood or skin samples from volunteer donors, the research project will look to provide an important piece in the puzzle to determine how autophagy is important for brain health.
Autophagy is a process of nutrient recycling and elimination of unnecessary or damaged cellular material in cells, leading to a periodic clean-up of the cell interior and recycling of nutrients during times of low resources.
Trinity College, Dublin:Hepatitis C research
Stemnovate partners Prof Cliona O’Farrelly at Trinity College, Ireland to find out why some people can block infection by hepatitis C, in a bid to improve treatment. Prof Cliona O’Farrelly has made exciting discoveries about the liver immune system, and now she is keen to know what antiviral strategies we can learn from women whose immune systems seem to block hepatitis C virus from establishing an infection. Stemnovate has expertise in reprogramming cells to multiple cell types. The adult cells, blood cells or skin cells are reprogrammed with human genes expressed in embryonic stages but without the use of any embryos. The cells acquire properties like Embryonic stem cells that can then differentiate to form neurons, heart cells and liver cells.
European Space Agency : Microgravity Application Promotion Programme
Stemnovate has partnered with multinational collaborators on a project coordinated by the MEDES Institute of space medicine and physiology.
The project focuses on developing technology to study the effect on astronauts' musculoskeletal systems while living in space. Despite extensive use of exercise countermeasures, the astronauts' body displays a reduction in muscle volume and strength, bone mass decrease, and microarchitectural alterations. In addition to spaceflight-related conditions, ageing and sedentariness of the population are often accompanied by sarcopenia (loss of muscle mass and strength) and osteoporosis (bone weakness), conditions without efficient treatment available. There is, therefore, an urgent need for the development of new therapeutic strategies acting on the two arms of the musculoskeletal system.
Babraham Institute : Increasing efficiency of cellular reprogramming for cell therapy
Stemnovate established a collaboration with Dr Maria Christophorou at Babraham Institute to identify epigenetic and signalling mechanisms involved in cellular reprogramming that can potentially increase efficiency and safety for cellular therapies.
The project entitled ‘Reprogramming cells from the outside in’ focuses on studying chromatin-modifying enzyme peptidyl arginine deiminase IV (PADI4)modulation as a mode of enhancing cell reprogramming The project received funding under the BBSRC Collaborative Training Partnership.